. 2016 Jul 25;10(8):1363–1373. doi: 10.1016/j.molonc.2016.07.004

Table 1.

Overview: Identification of potential biomarkers related to the PIK3CA status in relation to PFS after first line AI therapy.

Factor	TCGA‐set									AI‐set
	Relationships with PIK3CA status and Luminal subtype for 286 patients						Relationships with overall survival available for 272 patients			Relationships with progression‐free survival in 75 patients who received first‐line AI therapy
	PIK3CA status			Subtype			Univariate analysis			Univariate analysis			Mutivariate analysis: each factor added to the base model of traditional factorsc
	Wild‐type	Mutated	P	Luminal A	Luminal B	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
	Wild‐type	Mutated	MWa	Luminal A	Luminal B	MWa	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Median expression levels for:
LRG1	0.10	1.06	<0.001	0.65	0.35	0.139	0.83	0.70–0.99	0.033	0.69	0.55–0.87	0.002	0.70	0.54–0.90	0.006
PLCL1	−0.11	0.76	<0.001	0.45	−0.03	0.013	0.71	0.52–0.97	0.029	0.61	0.46–0.81	0.001	0.58	0.43–0.79	<0.001
FAM81B	0.27	1.64	<0.001	1.19	0.00	<0.001b	0.88	0.71–1.08	0.216	0.82	0.73–0.92	<0.001	0.83	0.73–0.94	0.004
CCNO	0.11	0.67	<0.001	0.41	0.23	0.319	0.97	0.75–1.27	0.832	0.84	0.73–0.96	0.010	0.84	0.73–0.97	0.018
NEK10	0.21	1.66	<0.001	1.29	−0.21	<0.001b	0.88	0.72–1.06	0.172	0.76	0.65–0.90	0.001	0.79	0.65–0.95	0.012
PGR	0.73	2.03	<0.001	1.81	0.45	<0.001b	0.91	0.77–1.06	0.221	0.84	0.74–0.95	0.006	0.85	0.72–0.99	0.039
SERPINA3	0.17	0.77	0.001	0.53	0.32	0.069	0.81	0.66–0.98	0.031	0.82	0.70–0.97	0.020	0.85	0.70–1.04	NS
SORBS2	−0.37	0.33	<0.001	0.30	−0.86	<0.001b	0.82	0.63–1.07	0.142	0.69	0.56–0.86	0.001	0.71	0.56–0.89	0.004
VTCN1	−0.90	0.37	<0.001	0.30	−1.44	<0.001b	0.91	0.77–1.08	0.284	0.84	0.73–0.97	0.021	0.87	0.73–1.03	NS
hsa‐miR‐449a	0.93	1.59	0.011	1.13	1.21	0.817	0.84	0.66–1.07	0.166	0.93	0.87–0.99	0.022	0.93	0.87–0.99	0.030
hsa‐miR‐301a‐3p	3.36	2.88	0.003	2.84	3.74	<0.001b	1.38	1.00–1.89	0.047	1.30	1.01–1.68	0.043	1.21	0.91–1.61	NS
hsa‐miR‐205‐5p	9.46	10.82	<0.001	10.49	9.04	<0.001b	1.00	0.86–1.16	0.988	0.93	0.84–1.04	0.209

Mann Whitney (MW) nonparametric test was applied for the evaluation of the expression levels in relationship to PIK3CA status (wild type vs mutant) or luminal subtype (A vs B).

Significant after the Bonferroni correction for multiple testing (P = 0.05/12 = 0.004).

Each factor added to the base model of traditional factors including age, disease free interval, dominant site of relapse, PR and HER2 status.